OTCMKTS:BSTGBiostage Stock Price, Forecast & News

$2.89

+0.09 (+3.21 %)

(As of 05/25/2020 08:55 AM ET)

Add

Compare

Today's Range

$2.89

Now: $2.89▼

$2.90

50-Day Range

$2.80

MA: $3.36▼

$4.20

52-Week Range

$1.79

Now: $2.89▼

$4.88

Volume2,230 shs

Average Volume1,524 shs

Market Capitalization$24.68 million

P/E RatioN/A

Dividend YieldN/A

Beta0.04

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Biostage.

2.8 Community Rank

Outperform Votes
Biostage has received 50 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Biostage has received 39 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Biostage has received 56.18% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote “Outperform” if you believe BSTG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BSTG will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Biostage does not currently pay a dividend.
Dividend Growth
Biostage does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biostage insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.70% of the stock of Biostage is held by insiders.
Percentage Held by Institutions
Only 0.18% of the stock of Biostage is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Biostage is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biostage is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biostage has a P/B Ratio of 22.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.56 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:BSTG

Previous Symbol

CUSIPN/A

CIK1563665

Webwww.biostage.com

Phone774-233-7300

Debt

Debt-to-Equity Ratio0.09

Current Ratio1.19

Quick Ratio1.19

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.13 per share

Price / Book22.23

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-8,330,000.00

Net MarginsN/A

Return on Equity-735.80%

Return on Assets-400.00%

Miscellaneous

Employees15

Outstanding Shares8,540,000

Market Cap$24.68 million

Next Earnings Date8/11/2020 (Estimated)

OptionableNot Optionable

Receive BSTG News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTG and its competitors with MarketBeat's FREE daily newsletter.

Biostage (OTCMKTS:BSTG) Frequently Asked Questions

How has Biostage's stock been impacted by COVID-19 (Coronavirus)?

Biostage's stock was trading at $3.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BSTG stock has decreased by 17.4% and is now trading at $2.89. View which stocks have been most impacted by Coronavirus.

When is Biostage's next earnings date?

Biostage is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Biostage.

How were Biostage's earnings last quarter?

Biostage Inc (OTCMKTS:BSTG) issued its earnings results on Thursday, May, 14th. The company reported ($0.24) EPS for the quarter. View Biostage's earnings history.

Has Biostage been receiving favorable news coverage?

Press coverage about BSTG stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biostage earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutBiostage.

Who are some of Biostage's key competitors?

Some companies that are related to Biostage include Venus Concept (VERO), BRAINSWAY LTD/S (BWAY), T2 Biosystems (TTOO), SANUWAVE Health (SNWV), AIT Therapeutics (AITB), Pro-Dex (PDEX), Nephros (NEPH), Nephros (NEPHD), Apollo Endosurgery (APEN), STRATA Skin Sciences (SSKN), Neuronetics (STIM), Motus GI (MOTS), Sensus Healthcare (SRTS), Arch Therapeutics (ARTH) and Neovasc (NVCN). View all competitors.

What other stocks do shareholders of Biostage own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biostage investors own include Allena Pharmaceuticals (ALNA), Biostage (BSTGD), Corbus Pharmaceuticals (CRBP), Ring Energy (REI), Ring Energy (REI), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB), Apellis Pharmaceuticals (APLS), Antero Resources (AR) and Ardelyx (ARDX).

Who are Biostage's key executives?

Biostage's management team includes the following people:

Mr. James J. McGorry, CEO & Director (Age 63)
Mr. Thomas W. McNaughton, CFO & Sec. (Age 59)
Yu Hong, Pres (Age 46)
Ms. Ginger A. Abraham-Freel, Director of Quality & Operations
Dr. William L. Fodor Ph.D., Chief Scientific Officer (Age 60)

What is Biostage's stock symbol?

Biostage trades on the OTCMKTS under the ticker symbol "BSTG."

How do I buy shares of Biostage?

Shares of BSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biostage's stock price today?

One share of BSTG stock can currently be purchased for approximately $2.89.

How big of a company is Biostage?

Biostage has a market capitalization of $24.68 million. Biostage employs 15 workers across the globe.

What is Biostage's official website?

The official website for Biostage is www.biostage.com.

How can I contact Biostage?

Biostage's mailing address is 84 October Hill Road Suite 11, Holliston MA, 01746. The company can be reached via phone at 774-233-7300 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff